Updated Results From the Phase 1/2 MajesTEC-1 Study of Teclistamab, a B-Cell Maturation Antigen x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma Popat, R., Usmani, S. Z., Garfall, A., van de Donk, N., Nahi, H., San-Miguel, J. F., Oriol, A., Nooka, A., Martin, T., Rosinol, L., Chari, A., Karlin, L., Benboubker, L., Mateos, M., Bahlis, N., Moreau, P., Besemer, B., Martinez-Lopez, J., Sidana, S., Pei, L., Trancucci, D., Verona, R., Girgis, S., Olyslager, Y., Jaffe, M., Uhlar, C., Stephenson, T., Van Rampelbergh, R., Banerjee, A., Goldberg, J. D., Kobos, R., Krishnan, A. WILEY. 2022: 35-36

View details for Web of Science ID 000776484300034